公开(公告)号：EP3307728A1

公开(公告)日：2018-04-18

申请号：EP16808476.2

申请日：2016-06-10

申请人： Dana Farber Cancer Institute, Inc.

发明人： HAMMERMAN, Peter ,  WONG, Kwok-kin ,  GRAY, Nathanael, S.

IPC分类号： C07D401/14 ,  A61K31/421

CPC分类号： A61K31/506 ,  A61K31/4162 ,  A61K31/519 ,  A61K31/52 ,  A61K31/53 ,  A61K31/551 ,  A61K31/5517 ,  A61K31/69 ,  A61K45/06 ,  A61P35/00 ,  A61K2300/00

摘要： The present disclosure provides combination therapy of a transcription inhibitor and a kinase inhibitor. The combination of the transcription inhibitor and the kinase inhibitor may be useful in treating and/or preventing in a subject a proliferative disease, such as proliferative a disease that is resistant to the transcription inhibitor alone or the kinase inhibitor alone. In certain embodiments, the proliferative disease is a cancer. The combination of the transcription inhibitor and the kinase inhibitor is expected to be synergistic.

公开(公告)号：EP3004877A1

公开(公告)日：2016-04-13

申请号：EP14807512.0

申请日：2014-06-02

申请人： Dana-Farber Cancer Institute, Inc.

发明人： HAMMERMAN, Peter

IPC分类号： G01N33/50

CPC分类号： C12Q1/6886 ,  C12N15/1138 ,  C12N2310/11 ,  C12N2320/30 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/118 ,  C12Q2600/156 ,  C12Q2600/158 ,  G01N33/57407 ,  G01N33/57423 ,  G01N33/57492 ,  G01N2333/4703 ,  G01N2333/70503 ,  G01N2333/70596 ,  G01N2500/00 ,  G01N2500/04 ,  G01N2500/10 ,  G01N2800/50 ,  G01N2800/52

摘要： The present invention relates to methods for identifying, assessing, preventing, and treating cancer (
e.g ., head, neck, and/or lung cancers in humans). A variety of PD-LI isoforni biomarkers are pro v ided, wherein alterations in the copy number of one or more of the biomarkers and/or alterations in the amount, structure, and/or acti vity of one or more of the biomarkers is associated with cancer status and indicates amenability to treatment or prevention by modulating PD-1 and/or PD-L! levels.

摘要翻译： 本发明涉及一种用于识别，assesing，预防和治疗癌症的方法（E. G.，头部，颈部和/或肺在人类癌症中）。 提供各种PD-L1 isoforni生物标志物，worin在一个或多个在数量，结构中的生物标记和/或变更的，和/或一种或多种生物标记的活动的拷贝数改变与癌症状态有关的 并指示顺从治疗或预防通过调节PD-1和/或PD-L！ 水平。